Free Trial

Lantern Pharma (LTRN) Competitors

$6.27
+0.04 (+0.64%)
(As of 05/24/2024 04:00 PM ET)

LTRN vs. BTAI, LPTX, GRTS, PRPH, TNXP, ATAI, ENTA, XBIT, IMMP, and ME

Should you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include BioXcel Therapeutics (BTAI), Leap Therapeutics (LPTX), Gritstone bio (GRTS), ProPhase Labs (PRPH), Tonix Pharmaceuticals (TNXP), Atai Life Sciences (ATAI), Enanta Pharmaceuticals (ENTA), XBiotech (XBIT), Immutep (IMMP), and 23andMe (ME). These companies are all part of the "medical" sector.

Lantern Pharma vs.

Lantern Pharma (NASDAQ:LTRN) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, community ranking, dividends, risk, analyst recommendations and institutional ownership.

BioXcel Therapeutics received 226 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 67.23% of users gave BioXcel Therapeutics an outperform vote.

CompanyUnderperformOutperform
Lantern PharmaOutperform Votes
12
75.00%
Underperform Votes
4
25.00%
BioXcel TherapeuticsOutperform Votes
238
67.23%
Underperform Votes
116
32.77%

BioXcel Therapeutics has a consensus price target of $16.71, suggesting a potential upside of 798.62%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe BioXcel Therapeutics is more favorable than Lantern Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lantern Pharma
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
BioXcel Therapeutics
0 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.43

Lantern Pharma has higher earnings, but lower revenue than BioXcel Therapeutics. Lantern Pharma is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lantern PharmaN/AN/A-$15.96M-$1.63-3.85
BioXcel Therapeutics$1.38M50.58-$179.05M-$5.18-0.36

In the previous week, Lantern Pharma and Lantern Pharma both had 3 articles in the media. Lantern Pharma's average media sentiment score of 1.19 beat BioXcel Therapeutics' score of 0.94 indicating that Lantern Pharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lantern Pharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
BioXcel Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantern Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 6.9% of Lantern Pharma shares are held by insiders. Comparatively, 35.8% of BioXcel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Lantern Pharma has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -8,715.72%. Lantern Pharma's return on equity of -41.17% beat BioXcel Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Lantern PharmaN/A -41.17% -38.41%
BioXcel Therapeutics -8,715.72%-890.63%-154.37%

Summary

Lantern Pharma and BioXcel Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LTRN vs. The Competition

MetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$67.47M$6.50B$5.00B$8.04B
Dividend YieldN/A2.79%2.83%3.96%
P/E Ratio-3.8521.91158.7118.37
Price / SalesN/A240.422,542.2474.09
Price / CashN/A19.2232.9728.78
Price / Book1.675.864.964.40
Net Income-$15.96M$120.76M$103.77M$213.17M
7 Day Performance7.73%-3.09%-1.32%-1.39%
1 Month Performance14.00%0.98%3.36%3.10%
1 Year Performance29.55%-4.55%5.37%7.51%

Lantern Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BTAI
BioXcel Therapeutics
4.4707 of 5 stars
$1.86
+0.5%
$16.71
+798.6%
-90.1%$69.81M$1.38M-0.3674
LPTX
Leap Therapeutics
2.24 of 5 stars
$2.38
-3.6%
$11.00
+362.2%
-65.3%$60.93M$1.50M-1.0054Positive News
GRTS
Gritstone bio
1.6615 of 5 stars
$0.80
-2.5%
$4.75
+492.6%
-53.1%$87.03M$16.34M-0.65231
PRPH
ProPhase Labs
2.4123 of 5 stars
$5.05
-5.3%
$11.00
+117.8%
-48.4%$96.35M$28.72M-4.68113Positive News
TNXP
Tonix Pharmaceuticals
2.3786 of 5 stars
$0.18
+0.6%
$5.50
+3,033.9%
-89.5%$16.77M$10.25M-0.03103Gap Up
ATAI
Atai Life Sciences
1.8192 of 5 stars
$1.61
-1.2%
$10.50
+552.2%
-9.0%$269.53M$310,000.00-6.4483
ENTA
Enanta Pharmaceuticals
3.5111 of 5 stars
$12.03
-0.4%
$19.00
+57.9%
-51.7%$254.80M$79.20M-1.93145Positive News
XBIT
XBiotech
0 of 5 stars
$8.31
-0.6%
N/A+51.9%$253.12M$4.01M-8.1582
IMMP
Immutep
1.093 of 5 stars
$2.84
-5.0%
$8.50
+199.3%
+33.3%$249.72M$3.50M0.002,021Positive News
ME
23andMe
0.1802 of 5 stars
$0.51
+0.7%
$0.47
-8.4%
-75.3%$247.79M$219.64M-0.37769Gap Up

Related Companies and Tools

This page (NASDAQ:LTRN) was last updated on 5/28/2024 by MarketBeat.com Staff

From Our Partners